Abstract P3001: Regulation Of Perivascular Adipose Tissue By Follistatin In Hypertension

Follistatin lowers BP and improves resistance artery health in spontaneously hypertensive rats (SHR), a model of essential HTN. Functionally, follistatin improves smooth muscle contraction and endothelium-dependent relaxation. Structurally, increased medial collagen was inhibited. Vascular ROS were also reduced. Perivascular adipose tissue (PVAT) regulates vascular tone via release of vasoactive substances. Oxidative stress in PVAT, as in HTN, induces release of contractile agents. Transition from white to brown PVAT is associated with decreased risk of CVD. We analyze effects of follistatin on PVAT and its regulation of vessel function in SHR and normotensive Wistar Kyoto (WKY) rats. White and brown PVAT were dissected from treated rats; arteries were isolated from untreated donors. PVAT was introduced near strain-matched donor arteries and assessed for ROS levels and contractility using DHE and wire myography, respectively. In some vessels, endothelium was denuded to assess its contribution to contraction. Follistatin reduced ROS, hypercontractility, and improved relaxation in a PVAT-dependent manner. Brown PVAT induced significant anti-contractile and antioxidant effects. Elevated expression of adipose tissue browning markers and decreased adipocyte area with follistatin, support PVAT browning effects. Endothelium removal results in augmented vessel constriction, effects reduced by follistatin. Follistatin improves SHR smooth muscle tone in a PVAT-dependent manner, likely through the inhibition of vascular ROS and browning of PVAT. Future work will profile PVAT effects of follistatin through unbiased proteomic analysis. Although most vessels are surrounded by PVAT, studies of PVAT-vessel interaction in HTN are few. By characterizing PVAT dysfunction, we aim to outline specific PVAT-mediated pathways involved in lowering BP and improving vascular function and structure. Results will provide new insights into PVAT-targeted therapy for essential HTN, allowing potential translation of benefits to obesity and other diseases exhibiting PVAT dysfunction.